Olfactory threshold predicts treatment response in relapsing multiple sclerosis

被引:3
|
作者
Bsteh, Gabriel [1 ]
Hegen, Harald [2 ]
Berek, Klaus [2 ]
Altmann, Patrick [1 ]
Auer, Michael [2 ]
Di Pauli, Franziska [2 ]
Haider, Lukas [3 ]
Leutmezer, Fritz [1 ]
Rommer, Paulus [1 ]
Walchhofer, Lisa-Maria [4 ]
Wurth, Sebastian [5 ]
Zinganell, Anne [2 ]
Deisenhammer, Florian [2 ]
Berger, Thomas [1 ]
机构
[1] Med Univ Vienna, Dept Neurol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
[2] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria
[3] Med Univ Vienna, Dept Neuroradiol, Vienna, Austria
[4] Med Univ Innsbruck, Dept Neuroradiol, Innsbruck, Austria
[5] Med Univ Graz, Dept Neurol, Graz, Austria
关键词
Multiple sclerosis; olfactory threshold; disease-modifying treatment; relapse; MRI; treatment response; INTERFERON-BETA; DYSFUNCTION; SMELL; MRI;
D O I
10.1177/13524585221079744
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Olfactory threshold (OT) is associated with short-term inflammatory activity in relapsing multiple sclerosis (RMS). Objective: We aimed to investigate OT for prediction of treatment response in RMS. Methods: In this 5-year prospective study on 123 RMS patients, OT was measured at disease-modifying treatment (DMT) initiation (M0), after 3 months (M3), and 12 months (M12) by Sniffin' Sticks test. Primary endpoint was defined as an absence of relapse during the observation period, with Expanded Disability Status Scale (EDSS) progression and magnetic resonance imaging (MRI) activity being the secondary endpoints. Optimal cutoff values were determined by receiver operating characteristic analyses and their predictive value assessed by multivariable Cox regression models. Results: Higher OT scores at M0, M3, and M12 were independently associated with decreased relapse probability with the strongest risk reduction at M3 (hazard ratio (HR) = 0.44, p < 0.001). Improvement of OT scores from M0 to M3 (Delta OTM3) was also associated with reduced relapse risk (HR = 0.12, p < 0.001). OT score > 6.5 at M3 was the strongest predictor of relapse freedom (HR = 0.10, p < 0.001) with high diagnostic accuracy (positive predictive value (PPV) = 87%), closely followed by Delta OTM3 > 0.5 (HR = 0.12, p < 0.001, PPV = 86%). Conclusions: OT is an independent predictor of freedom of disease activity upon DMT initiation within 5 years and may be a useful biomarker of treatment response.
引用
收藏
页码:1541 / 1552
页数:12
相关论文
共 50 条
  • [41] B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis
    Tacke, Sabine
    Braune, Stefan
    Rovituso, Damiano M.
    Ziemssen, Tjalf
    Lehmann, Paul, V
    Dikow, Heidi
    Bergmann, Arnfin
    Kuerten, Stefanie
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (03):
  • [42] Daclizumab for the treatment of relapsing-remitting multiple sclerosis
    Herwerth, Marina
    Hemmer, Bernhard
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (06) : 747 - 753
  • [43] Briumvi: a breakthrough in the treatment of relapsing multiple sclerosis: a review
    Azhar, Ayesha
    Taimuri, Muskan Asim
    Shamat, Shamat Fathi
    Ikram, Areeba
    Ali, Sajjad
    Ali, Tehreem
    Khabir, Yumna
    ANNALS OF MEDICINE AND SURGERY, 2023, 85 (10): : 4909 - 4912
  • [44] Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis
    Thomas, Katja
    Proschmann, Undine
    Ziemssen, Tjalf
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (15) : 1649 - 1660
  • [45] Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    Menge, Til
    Dubey, Divyanshu
    Warnke, Clemens
    Hartung, Hans-Peter
    Stuve, Olaf
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1131 - 1139
  • [46] Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
    Hersh, Carrie M.
    Cohen, Jeffrey A.
    IMMUNOTHERAPY, 2014, 6 (03) : 249 - 259
  • [47] Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Fox, Edward J.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1789 - 1797
  • [48] Guiding Treatment Deescalation in Relapsing Remitting Multiple Sclerosis
    Mueller, Jannis
    Sharmin, Sifat
    Lorscheider, Johannes
    Horakova, Dana
    Havrdova, Eva
    Izquierdo Ayuso, Guillermo
    Eichau Madueno, Sara
    Patti, Francesco
    Grammond, Pierre
    Buzzard, Katherine
    Skibina, Olga
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Grand'Maison, Francois
    Alroughani, Raed
    Lechner-Scott, Jeannette
    Spitaleri, Daniele L. A.
    Barnett, Michael
    Cartechini, Elisabetta
    Sa, Maria Jose
    Gerlach, O.
    van der Walt, Anneke
    Butzkueven, Helmut
    Prevost, Julie
    Castillo-Trivino, Tamara
    Yamout, Bassem I.
    Khoury, Samia
    Yaldizli, Ozgur
    Derfuss, Tobias
    Granziera, Cristina
    Kuhle, Jens
    Kappos, Ludwig
    Roos, Izanne
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 105 - 107
  • [49] Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
    Sartori, Arianna
    Carle, Dawn
    Freedman, Mark S.
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (07) : 1019 - 1027
  • [50] Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis
    Osherov, Michael
    Milo, Ron
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (10) : 1037 - 1047